173 related articles for article (PubMed ID: 30142419)
1. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Scott EC; Hari P; Kumar S; Fraser R; Davila O; Shah N; Gale RP; Diaz MA; Agrawal V; Cornell RF; Ganguly S; Akpek G; Freytes C; Hashmi S; Malek E; Kamble RT; Lazarus H; Solh M; Usmani SZ; Kanate AS; Saad A; Chhabra S; Gergis U; Cerny J; Kyle RA; Lee C; Kindwall-Keller T; Assal A; Hildebrandt GC; Holmberg L; Maziarz RT; Nishihori T; Seo S; Kumar S; Mark T; D'Souza A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2443-2449. PubMed ID: 30142419
[TBL] [Abstract][Full Text] [Related]
2. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
4. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
5. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
[TBL] [Abstract][Full Text] [Related]
6. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
Hari PN; Zhang MJ; Roy V; Pérez WS; Bashey A; To LB; Elfenbein G; Freytes CO; Gale RP; Gibson J; Kyle RA; Lazarus HM; McCarthy PL; Milone GA; Pavlovsky S; Reece DE; Schiller G; Vela-Ojeda J; Weisdorf D; Vesole D
Leukemia; 2009 Aug; 23(8):1528-34. PubMed ID: 19322205
[TBL] [Abstract][Full Text] [Related]
7. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
8. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
9. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
[TBL] [Abstract][Full Text] [Related]
10. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
11. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
Çiftçiler R; Göker H; Demiroğlu H; Haznedaroğlu İC; Sayınalp N; Aksu S; Özcebe O; Büyükaşık Y
Turk J Haematol; 2021 Feb; 38(1):33-40. PubMed ID: 32539315
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
[TBL] [Abstract][Full Text] [Related]
15. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
17. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Munshi PN; Vesole D; Jurczyszyn A; Zaucha JM; St Martin A; Davila O; Agrawal V; Badawy SM; Battiwalla M; Chhabra S; Copelan E; Kharfan-Dabaja MA; Farhadfar N; Ganguly S; Hashmi S; Krem MM; Lazarus HM; Malek E; Meehan K; Murthy HS; Nishihori T; Olin RL; Olsson RF; Schriber J; Seo S; Shah G; Solh M; Tay J; Kumar S; Qazilbash MH; Shah N; Hari PN; D'Souza A
Cancer; 2020 Dec; 126(23):5077-5087. PubMed ID: 32965680
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
19. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
20. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
